Overview

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)
Phase:
Phase 2
Details
Lead Sponsor:
MedSIR
Collaborator:
Pfizer
Treatments:
Fulvestrant
Letrozole
Palbociclib